by ZACHARY BRENNAN CMS on Tuesday said it will only pay for Biogen’s Aduhelm and other FDA-approved anti-amyloid monoclonal antibodies for Alzheimer’s disease under CMS-approved randomized controlled trials. In a draft national coverage decision, which insurers nationwide are likely to follow, CMS said it’ll be looking for randomized controlled trials that “demonstrate a clinically meaningful benefit in cognition...
Tag: <span>Biogen</span>
Post
Biogen reverses course on compassionate use for ALS drug tofersen with plans to open program in July
Josh Sullivan Associate Editor Despite immense pressure from the ALS community, Biogen had repeatedly refused to open investigational drug tofersen for use outside of clinical trials. But now, caving to that demand, Biogen has reversed its stance. With a pivotal Phase III study in ALS ongoing and data expected to read out later this year, Biogen just...